

Proskauer» Global Capital Markets
IPO Study 2019

Principal Contacts

New York



Daniel L. Forman

Senior Counsel
Global Capital Markets
+1.212.969.3096
dforman@proskauer.com

Boston



Lily Desmond

Senior Counsel
Global Capital Markets
+1.617.526.9641
ldesmond@proskauer.com

Washington, D.C.



Karen Garnett

Partner
Global Capital Markets
+1.202.416.6850
kgarnett@proskauer.com



William J. Tuttle

Partner
Global Capital Markets
+1.202.416.6860
wtuttle@proskauer.com

London



Peter Castellon

Partner
Global Capital Markets
+44.20.7280.2091
pcastellon@proskauer.com



Maximilian Kirchner

Partner
Global Capital Markets
+44.20.7280.2074
mkirchner@proskauer.com

Chicago



Michael J. Choate

Partner
Global Capital Markets
+1.312.962.3567
mchoate@proskauer.com

Sao Paulo



Antonio Piccirillo

Partner
Head of Sao Paulo Office
Global Capital Markets
+1.212.969.3905
apiccirillo@proskauer.com

We hope you enjoy Proskauer's 2019 IPO Study.
Please feel free to contact any of the Global Capital
Markets attorneys listed here with any questions
on this report.

Contents

2018 Market Overview ₁

Trend Analysis ₄₃

Health Care ₅₉

Technology, Media & Telecommunications ₇₅

Consumer/Retail ₉₁

Financial Services ₁₀₇

Industrials ₁₂₁

Appendix A - Sponsor-Backed Issuers

Appendix B - Foreign Private Issuers

These materials are proprietary to Proskauer Rose LLP and may not be reproduced, transmitted or otherwise exploited in any media, in whole or in part, without the prior written authorization of Proskauer Rose LLP.

This publication includes the presentation of statistical information for illustrative purposes only and should not be relied on for any inference of correlative or causal relationships. Although we believe our study is an accurate representation of the IPO market that meets our study's criteria, there may be slight deviations from the actual market.

This publication is a service to our clients and friends of the firm. This publication is not intended to be comprehensive or to provide financial, investment, legal, tax or other professional advice or services. This publication is not a substitute for such professional advice or services, and it should not be acted on or relied upon or used as a basis for any investment or other decision or action that may affect you or your business. Before making any such decision you should consult a suitably qualified professional adviser. While reasonable effort has been made to ensure the accuracy of the information contained in this publication, this cannot be guaranteed and neither Proskauer Rose LLP nor any other related entity shall have any liability to any person or entity that relies on the information contained in this publication, including incidental or consequential damages arising from errors or omissions. Any such reliance is solely at the user's risk.

© 2019 Proskauer Rose LLP. All rights reserved.

Methodology

Population

Our proprietary database now includes 556 IPOs that priced from 2013 to 2018.

The criteria for our study include:

- Listing on a U.S. national securities exchange; and
- Minimum initial base deal of \$50mm in the first preliminary prospectus that included a price range filed with the SEC.

The total population that met our criteria in 2018 was 152 IPOs.

This study covers 94 IPOs (approximately 62% of the IPOs that met our criteria) that priced in 2018: 72 domestic issuers and 22 foreign private issuers (FPIs). Our population is reflective of the total population based on industry, size and geographic region.

Our trend analysis section covers 456 IPOs: 94 in 2018, 86 in 2017, 67 in 2016, 90 in 2015 and 119 in 2014.

Our study excludes blank check companies (BCCs), special purpose acquisition companies (SPACs), trusts, real estate investment trusts (REITs), business development companies (BDCs) and closed-end investment companies.

There are two appendices in our study for Sponsor-backed IPOs and FPIs that priced in 2018.

Sources and Analysis

Data compiled from publicly available: (i) registration statements on Form S-1, Form S-11 and Form F-1 and final prospectuses, (ii) SEC comment letters and (iii) as-filed underwriting agreements.

Market, sector, pricing, over-allotment, sponsor-backed and performance data are sourced from Dealogic.

Financial information (unless otherwise indicated) is based on the issuer's most recent audited fiscal year as disclosed in the final prospectus.

The term "average offer" in the "Aftermarket Performance" charts means the average percentage change from the IPO price to the closing price on one day, 30 days, 90 days or 180 days (excludes deals priced after August 1, 2018) after the initial trade date and includes market data available as of January 31, 2018 (our cut-off date).

Analysis of first round SEC comment letters and time to pricing excludes three issuers that either received SEC comments on a prior IPO registration statement or were previously reporting issuers.

Analysis of corporate governance items excludes Master Limited Partnerships (MLPs) and FPIs, given their unique corporate governance structures and available exemptions under stock exchange rules.

Non-Generally Accepted Accounting Principles (Non-GAAP) financial measures include Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), adjusted EBITDA, adjusted net income and free cash-flow.

2018 Market Overview

Sector Analysis

Health Care IPOs made up the largest percentage of deals in the overall IPO market.



U.S. Geographic Analysis

California and Massachusetts were the top U.S. states for IPO issuer headquarters.

State of Headquarters

- California - 33%
- Massachusetts - 21%
- Texas - 7%
- Georgia - 4%
- New York - 3%
- Other - 32%



83%

of California-based issuers were headquartered in the Bay Area.

State of Incorporation


- Delaware - 88%
- Nevada - 3%
- Washington - 3%
- Other - 6%

Delaware was the top U.S. state for IPO issuer states of incorporation.




Global Geographic Analysis

2018 saw a significant increase in IPOs from China as a percentage of the overall market, up to 16% from 8% in 2017. This was the highest percentage of Chinese issuers that we have seen in the last five years.




Deal Size & Market Capitalization at Pricing

Almost half of IPOs had a deal size of between \$100mm and \$249mm.



Deal Size*




Market Cap at Pricing

*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Exercise of Over-Allotment Option


The over-allotment option was exercised in approximately

77%
of IPOs.




Exercise of Over-Allotment Option


- Option exercised in full or part - 77%
- Option not exercised - 23%



Exercise of Over-Allotment Option by Sector



Exercise of Over-Allotment Option by Deal Size*



Exercise of Over-Allotment Option by Market Cap at Pricing



*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.



Pricing vs. Range

Approximately

61%

of IPOs priced
in range.






*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Confidential Submission

The SEC permits issuers to utilize a confidential submission process in connection with its review of IPO registration statements. This confidential review process has been expanded by the JOBS Act, the FAST Act and SEC guidance.

The only issuer in our study that did not confidentially submit was AXA Equitable Holdings, Inc.



Confidential Submission

- Issuers confidentially submitting - 99%
- Issuers not confidentially submitting - 1%

Time to IPO


The average number of days from an initial submission/filing of an IPO registration statement to pricing was

139


days.

Average Number of Days from First Submission/Filing to Pricing*


By Sector



By Deal Size**



By Market Cap at Pricing



*Excludes three prior SEC-reviewed issuers.

**Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.


Emerging Growth Companies (EGCs)

EGCs are a class of issuers established under the JOBS Act that are afforded greater flexibility in pursuing their IPOs. Generally, EGCs are issuers with less than \$1.07 billion of annual gross revenue during their most recently completed fiscal year.

Approximately

86%

of IPO issuers
were EGCs.



EGCs by Sector


Financial Information & EGCs

Most EGCs took advantage of the scaled financial disclosure requirements afforded to them under the JOBS Act.




Years of Audited Financial Statements*

- 2 Years - 81%
- 3 Years - 19%



Years of Selected Financial Statements*

- 2 Years - 71%
- 3 Years - 23%
- 5 Years - 6%



Years of Audited Financial Statements in Initial Draft Registration Statement**

- 1 Year - 15%
- 2 Years - 77%
- 3 Years - 8%

*Non-EGCs are excluded as well as two EGCs that provided financial statements since inception, which period was shorter than two years, and one EGC that only showed seven months of unaudited financial statements as the issuer was previously in bankruptcy. The JOBS Act provides scaled financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.


**Pursuant to the FAST Act, issuers are permitted to omit audited and interim financial statements in initial submissions for prior periods that would not otherwise be required in the prospectus at pricing.

EBITDA and/or Adjusted EBITDA

In addition to financial measures calculated in accordance with generally accepted accounting principles, many issuers disclose non-GAAP measures, including EBITDA and Adjusted EBITDA.


37%

of issuers disclosed EBITDA and/or Adjusted EBITDA.



Disclosure of EBITDA and/or Adjusted EBITDA

- EBITDA and/or Adjusted EBITDA disclosed - 37%
- Neither EBITDA nor Adjusted EBITDA disclosed - 63%



Disclosure of EBITDA and/or Adjusted EBITDA by Sector


Operating Metrics

Operating metrics are non-financial performance measures and vary by sector.

Operating metrics include measures such as backlog, paying users and customer retention rates.


Operating metrics
were disclosed
in the summary
financials in

32%
of IPOs.



Disclosure of Operating Metrics

- Operating metrics included - 32%
- Operating metrics not included - 68%



Disclosure of Operating Metrics by Sector

Based on review of summary financial information.

Flash Results

“Flash results” refer to estimated, unaudited financial results for a recently completed fiscal period that are disclosed before complete financial statements are available. They are typically presented as ranges and often cover only select financial line items or operating metrics. They are not required under accounting rules but are often presented for disclosure reasons, particularly the closer the offering date is to the date the financial statements become stale.



46 IPOs priced within 45 days after the end of the fourth fiscal quarter of 2017 or the first, second or third fiscal quarter of 2018. 23 of these 46 issuers (50%) included flash results.

26%

of issuers included flash results.

50%

of issuers pricing within 45 days of a quarter end included flash results.




For IPOs, audited annual financial statements for the most recently completed fiscal year need to be included no later than 45 days after the end of the fiscal year and unaudited interim financial statements for the most recently completed fiscal quarter (other than the fourth quarter) need to be included no later than 134 days after the date of the most recent balance sheet included in the registration statement. For example, first quarter unaudited financial statements go stale at the end of the 134th day after the first quarter and an issuer would need to file second quarter unaudited financial statements with its registration statement on the 135th day.

Pro Forma Financial Statements

The SEC rules require issuers to include standalone pro forma financial statements in connection with certain material acquisitions, dispositions or other significant transactions where disclosure would be material to investors.


13%

of issuers included
pro forma financial
statements.



Inclusion of Pro Forma Financial Statements


- Pro forma financial statements included - 13%
- Pro forma financial statements not included - 87%



Inclusion of Pro Forma Financial Statements by Sector

Accounting/Internal Controls

Almost half of issuers that went public disclosed a material weakness in internal control over financial reporting.




Issuers with a Going Concern Qualification

- Issuers with a going concern - 22%
- Issuers without a going concern - 78%






Issuers with a Material Weakness

- Issuers with a material weakness - 46%
- Issuers without a material weakness - 54%



Issuers with Restated Financial Statements

- Issuers with restated financials - 7%
- Issuers without restated financials - 93%




SEC Comments: Total First Round Comments

Average number of total first round comments decreased from 23 in 2017 to


20

in 2018.



Average Number of First Round SEC Comments by Sector

- Low
- Average
- Median
- High



Average Number of SEC Comments by Round

- First round comments
- Second round comments
- Third round comments


Excludes three prior SEC-reviewed issuers.

SEC Comments: Financial & Accounting Comments

Financial and accounting comments include those on the summary financial and selected financial data, capitalization, management's discussion & analysis (MD&A), historical financial statements (F-pages) and pro forma financial statements.


The average number of financial and accounting comments decreased from 10 in 2017 to

seven
in 2018.




Excludes three prior SEC-reviewed issuers.

SEC Comments: A Closer Examination




Cheap Stock Comments by Sector*

Overall: 53%



Revenue Recognition Comments by Sector

Overall: 37%




Segment Reporting Comments by Sector

Overall: 16%


Excludes three prior SEC-reviewed issuers.

*Cheap stock comments relate to the difference in valuation represented by (1) pre-IPO equity grants, typically in the form of options to purchase stock issued to officers or directors, and (2) the expected IPO price.



Non-GAAP Financial Measures Comments by Sector

Overall: 25%




Executive Compensation/Employment Arrangements Comments by Sector

Overall: 27%

Excludes three prior SEC-reviewed issuers.


Capital Structure

Issuers with multiple classes of common stock continued to be found predominantly in the TMT sector.



Issuers with Multiple Classes of Common Stock



- Issuers with multiple classes of common stock - 15%
- Issuers with a single class of common stock - 85%



Issuers with Multiple Classes of Common Stock by Sector

Overall: 15%

Excludes FPIs (subject to home jurisdiction governance rules).




Excludes FPIs (subject to home jurisdiction governance rules).

Board Structure: Director Independence




Size of Board at Pricing

- Average number of directors at pricing - 8



Size of Board at Pricing

- Average number of independent directors at pricing - 5



Board Independence at Pricing

- Majority independent directors at pricing - 76%
- Less than a majority of independent directors at pricing - 24%


Excludes FPIs (subject to home jurisdiction governance rules).

Board Structure: Classified Board

Approximately


92%

of issuers went
public with a
classified board.




Issuers with a Classified Board at Pricing

- Issuers with a classified board - 92%
- Issuers without a classified board - 8%



Pricing vs. Range -
Classified Board

- Above range
- In range
- Below range





Aftermarket
Performance -
Classified Board

- Issuers with a classified board
- Issuers without a classified board
- All IPOs



Excludes FPIs (subject to home jurisdiction governance rules).

Board Structure: Separation of Chair & CEO Roles




Excludes three issuers that did not have a Chair at the time of IPO and FPIs (subject to home jurisdiction governance rules).

Anti-Takeover Measures and Exclusive Forum Provisions




Excludes FPIs (subject to home jurisdiction governance rules).

Certain anti-takeover measures are implemented to spring into effect upon a trigger event, such as a significant stockholder's ownership position falling below a certain threshold.



Restrictions on Stockholder Ability to Call Special Meeting

- Yes - 76%
- Subject to trigger - 10%
- No - 14%



Exclusive Forum Provisions*

- Yes - 87%
- No - 13%

Excludes FPIs (subject to home jurisdiction governance rules).

Certain anti-takeover measures were implemented to spring into effect upon a trigger event, such as a significant stockholder's ownership position falling below a certain threshold.

*Exclusive forum provisions limit the courts in which certain types of stockholder litigation can be brought.

Equity Incentive Plan

Most issuers establish a new equity incentive plan upon going public and reserve a specified number of shares to issue as compensation to officers, directors and employees.


The average percentage of shares reserved under equity incentive plans was

8.5%

Approximately

40%

of issuers also established employee stock purchase programs.




Average Percentage of Shares Reserved Under Equity Incentive Plans by Sector

Secondary Component

IPOs with a secondary component provide for sales of shares by existing stockholders of the company.


18%

of IPOs had one or more selling stockholders.




IPOs with a Secondary Component

- IPOs with a secondary component - 18%
- IPOs without a secondary component - 82%



Pricing vs. Range - Secondary Component

- Above range
- In range
- Below range



Aftermarket Performance - Secondary Component

- IPOs with a secondary component
- IPOs without a secondary component
- All IPOs

Deals with one or more selling stockholders selling in the over-allotment option are not included.

Management Sales

Directors and/or officers participated as selling stockholders in the base offering of


47%

of IPOs with a secondary component.




Management Selling in Secondary Component of IPO

- Secondary IPOs with management selling - 47%
- Secondary IPOs without management selling - 53%



Pricing vs. Range - Management Sales

- Above range
- In range
- Below range





Aftermarket Performance - Management Sales


- Secondary IPOs with management selling
- Secondary IPOs without management selling
- All IPOs

Insiders Purchasing

Almost half of issuers disclosed directors, officers or existing stockholders purchasing in their IPO.




Does not include purchases through a Directed Share Program (DSP).



Insiders Purchasing in IPO by Deal Size*

Overall: 47%



Insiders Purchasing in IPO by Market Cap at Pricing


Overall: 47%

Excludes purchases through a DSP.

*Deal size consists of priced amount in base offering and excludes an exercise of the over-allotment option.


Insiders Purchasing

IPOs with insiders purchasing were more likely to price in or above range.



Pricing vs. Range - Insiders Purchasing in IPO

- Above range
- In range
- Below range



Aftermarket Performance - Insiders Purchasing in IPO


- IPOs with insiders purchasing
- IPOs without insiders purchasing
- All IPOs

Does not include purchases through a DSP.

Pre-IPO Private Placements


47%

of issuers issued equity securities within 12 months prior to submitting/filing IPO registration statements.



Issuers Privately Placing Equity Securities within 12 months prior to Submitting/Filing IPO Registration Statement

- Yes - 47%
- No - 53%



Pre-IPO Private Placements by Sector

Based on review of information disclosed in Part II, Item 15 of Form S-1 registration statements and Part II, Item 7 of Form F-1 registration statements.

Directed Share Programs (DSPs)

Directed Share Programs (DSPs) allow insiders, employees and other individuals that have relationships with the issuer to purchase stock in the IPO. At the request of the issuer, the underwriters reserve a certain amount of the shares in the IPO for purchase by DSP participants.


41%

of issuers
established DSPs.

The average size for
DSPs was


5%

of the base deal size.



Directed Share Programs (DSPs)

- Issuers that offered DSPs - 41%
- Issuers that did not offer DSPs - 59%



DSPs by Sector

Lock-ups

Typically, lock-up release rights are negotiated between the bookrunners and the issuer. The parties that control release rights may, prior to the expiration of the lock-up period, permit the issuer and/or certain stockholders to sell shares in an organized follow-on offering or freely into the open market.

Lock-up release rights were held solely by the lead left bookrunner in

9%


of IPOs.

71%

of issuers had a lock-up carve-out for issuances in connection with acquisitions or joint ventures.

Lock-up Release

- Lead left bookrunner only - 9%
- Multiple bookrunners - 91%



Carve-outs for Issuances in Connection with Acquisitions or Joint Ventures*


- 5% carve-out - 49%
- 7% carve-out - 5%
- 10% carve-out - 13%
- Uncapped carve-out - 4%
- Carve-out not included - 29%



*Carve-out from issuer lock-up for equity issuances in connection with acquisitions, joint-ventures and strategic transactions.

IPO Fees & Expenses

Underwriting fees ranged from \$2.8mm to \$67.5mm. The median value for the underwriting fee as a percentage of the base deal size was 7%.



Average Fees and Expenses as % of Base Deal

● Average
● Median



Fee Category	Low	Average	Median	High
Underwriting Fees*	\$2,800,000	\$15,255,898	\$10,132,500	\$67,500,000
Total IPO Expenses	\$1,055,000	\$5,624,453	\$4,052,528	\$88,100,000
Legal Expenses	\$375,000	\$2,241,141	\$1,850,000	\$15,000,000
Accounting Expenses	\$80,000	\$1,855,186	\$1,027,400	\$50,000,000
Printing Expenses	\$35,000	\$377,912	\$325,000	\$2,000,000

IPO Fees and Expenses




*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.

Trend Analysis

Sector Analysis




Deal Size and Market Capitalization at Pricing




*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Confidential Submission




**EGCs Electing to
Confidentially Submit**



**Issuers Electing to
Confidentially Submit***


*Includes both EGCs and Non-EGCs.

Time to IPO




Excludes prior SEC-reviewed issuers and an additional two issuers in 2014, one issuer in 2015, two issuers in 2016 and nine issuers in 2017 with time from first submission/filing to pricing greater than 18 months.

Financial Information & EGCs




**EGCs that Included
Two Years of Audited
Financial Statements**




**EGCs that Included
Two Years of Selected
Financial Statements**

Excludes two EGCs in 2015, three EGCs in 2016, one EGC in 2017 and two EGCs in 2018 that provided financial statements since inception, which period, in each case, was less than two years, and one that only showed seven months of unaudited financial statements as the issuer was previously in bankruptcy.

EBITDA, Adjusted EBITDA and Operating Metrics




**Disclosure of EBITDA
and/or Adjusted
EBITDA**




**Disclosure of
Operating Metrics***

*Based on review of summary financial information.


Pre-Revenue Issuers and Issuers with a Net Loss




Accounting/Internal Controls



Issuers with a Going Concern Qualification




Issuers with a Material Weakness




Issuers with Restated Financials

SEC Comments

There continues to be a year-over-year decrease in the average number of first round comments received by issuers from the SEC.



Average Number of First Round SEC Comments




Average Number of Financial and Accounting Comments*


Excludes prior SEC-reviewed issuers.

*Financial and accounting-related comments include those on the summary financial and selected financial data, capitalization, management's discussion & analysis (MD&A), historical financial statements (F-pages) and pro forma financial statements.

SEC Comments




**Percentage of
IPOs with Revenue
Recognition
Comments**




**Percentage of IPOs
with Non-GAAP
Financial Comments**

Excludes prior SEC-reviewed issuers.

Secondary Component and Insiders Purchasing




Percentage of IPOs
with a Secondary
Component



Percentage of
IPOs with Insiders
Purchasing*


*Does not include purchases through a DSP

Directed Share Programs (DSPs)




Sponsor-backed IPOs

There continues to be a decrease in the percentage of IPOs that were backed by sponsors.




Percentage of IPOs that are Sponsor-backed

IPO Fees and Expenses



Average IPO Fees and Expenses*



IPO Fees and Expenses as a Percentage of Base Deal Size

*Excludes underwriting fees.

Health Care

Health Care Market Overview

Health Care IPOs

42%


of overall market



97%


of Health Care issuers in our study were biotech or biopharmaceutical companies.

Sector Overview




- Health Care IPOs - 42%
- All other IPOs - 58%


Region of Headquarters




Moderna, Inc., which priced in December 2018, was the largest biotech firm to go public with a deal size of approximately \$604mm.



Deal Size*



Over-Allotment Option Exercised





Market Cap at Pricing


- Small-cap (<\$350mm) - 26%
- Mid-cap (\$350mm-\$1bn) - 59%
- Large-cap (\$1bn+) - 15%

*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option

Market Performance







Emerging Growth Companies (EGCs)





*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.

Accounting/Internal Controls and Flash Results




SEC Comments




Excludes prior SEC-reviewed issuers.

Timing







Average Number of Days from First Submission/Filing to Pricing



Health Care Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

Corporate Governance





Excludes FPIs (subject to home jurisdiction governance rules).

*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

**Excludes three issuers that did not have a Chair at the time of IPO.



Secondary Component and Directed Share Programs (DSPs)



Deal Structure: Insiders Purchasing in IPO

77%

of Health Care
IPOs had insiders
purchasing.




Percentage of IPO Purchased by Health Care Insiders*

- 5.0%-9.9% purchased - 3%
- 10.0%-19.9% purchased - 7%
- 20.0% or more purchased - 90%

Excludes purchases through a DSP.


*Population consists of IPOs with insiders purchasing.

Deal Structure: Insiders Purchasing in IPO



Pricing vs. Range

- Above range
- In range
- Below range




Aftermarket Performance

- Health Care IPOs with insiders purchasing
- All other IPOs with insiders purchasing


Excludes purchases through a DSP.

Lock-ups and Carve-outs




Lock-up Release

- Lead left bookrunner only - 8%
- Multiple bookrunners - 92%




**Carve-out for Acquisitions/
Joint Ventures**




**Company Lock-up/
Carve-out by Cap**

- 5% carve-out - 82%
- 7% carve-out - 9%
- 10% carve-out - 9%

Fees and Expenses



*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.



Technology, Media & Telecommunications

TMT Market Overview

Technology, Media & Telecommunications
IPOs


30%

of overall market






Sector Overview

- TMT IPOs - 30%
- All other IPOs - 70%




Region of
Headquarters




*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Market Performance



Pricing vs. Range



- Above range
- In range
- Below range



Aftermarket Performance


- TMT IPOs
- All other IPOs

Emerging Growth Companies (EGCs)



Years of Audited Financial Statements*

- 2 Years - 65%
- 3 Years - 35%







Years of Selected Financial Statements*


- 2 Years - 62%
- 3 Years - 38%

*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.



Accounting/Internal Controls and Flash Results



Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




SEC Comments




Excludes prior SEC-reviewed issuers.

Timing







Average Number of Days From First Submission/Filing to Pricing



TMT Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

Corporate Governance





Excludes FPIs (subject to home jurisdiction governance rules).



*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

**Excludes three issuers that did not have a Chair at the time of IPO.

Secondary Component and Directed Share Programs (DSPs)




Insiders Purchasing in IPO




Excludes purchases through a DSP.

Lock-ups and Carve-outs




Lock-up Release

- Lead left bookrunner only - 14%
- Multiple bookrunners - 86%




Carve-out for Acquisitions/Joint Ventures




Company Lock-up/Carve-out by Cap

- 5% carve-out - 57%
- 7% carve-out - 6%
- 10% carve-out - 31%
- Uncapped - 6%

Fees and Expenses



*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.




Consumer/ Retail

Consumer/Retail Market Overview

Consumer/Retail
IPOs


12%

of overall market






Sector Overview

- Consumer/Retail IPOs - 12%
- All other IPOs - 88%





Region of
Headquarters





*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Market Performance







Emerging Growth Companies (EGCs)




*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.



Accounting/Internal Controls and Flash Results



Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




SEC Comments




Excludes prior SEC-reviewed issuers.

Timing




Average Number of Days From First Submission/Filing to Pricing




Consumer/Retail Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

Corporate Governance




Controlled Company Exemption*




Board Composition

- Average number of directors
- Average number of independent directors



Separation of Chair and CEO Roles**






Multiple Classes of Common Stock

Excludes FPIs (subject to home jurisdiction governance rules).



*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

**Excludes three issuers that did not have a Chair at the time of IPO.

Secondary Component and Directed Share Programs (DSPs)




Deal Structure: Insiders Purchasing in IPO




Excludes purchases through a DSP.

Lock-ups and Carve-outs



Lock-up Release

- Lead left bookrunner only - 0%
- Multiple bookrunners - 100%




Carve-out for Acquisitions/Joint Ventures




Company Lock-up/Carve-out by Cap

- 5% carve-out - 58%
- 7% carve-out - 14%
- 10% carve-out - 14%
- Uncapped - 14%

Fees and Expenses



*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.



Financial Services

Financial Services Market Overview

Financial Services
IPOs

6%


of overall market




50%

of the financial
services issuers in our
study were commercial
savings banks.


Sector Overview




- Financial Services IPOs - 6%
- All other IPOs - 94%



Region of
Headquarters



Deal Size*



Over-Allotment Option Exercised





Market Cap at Pricing


- Small-cap (<\$350mm) - 33%
- Mid-cap (\$350mm-\$1bn) - 34%
- Large-cap (\$1bn+) - 33%

*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.


Market Performance



Emerging Growth Companies (EGCs)




Emerging Growth Companies (EGCs)



Years of Audited Financial Statements*

● 2 Years - 100%







Years of Selected Financial Statements*

● 2 Years - 25%


● 3 Years - 75%

*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.



Accounting/Internal Controls and Flash Results



Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




SEC Comments




Excludes prior SEC-reviewed issuers.

Timing







Average Number of Days From First Submission/Filing to Pricing



Financial Services Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

Corporate Governance





Excludes FPIs (subject to home jurisdiction governance rules).




*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

**Excludes three issuers that did not have a Chair at the time of IPO.



Secondary Component and Directed Share Programs (DSPs)



Lock-ups and Carve-outs



Fees and Expenses




*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.

Industrials


Industrials Market Overview

Industrials IPOs
6%
of overall market






Sector Overview

- Industrials IPOs - 6%
- All other IPOs - 94%





Country of
Headquarters




*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Market Performance







Emerging Growth Companies (EGCs)




*Non-EGCs are excluded



Accounting/Internal Controls and Flash Results



Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




SEC Comments




Excludes prior SEC-reviewed issuers.

Timing




Average Number of Days From First Submission/Filing to Pricing




Industrials Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

Corporate Governance




Controlled Company Exemption*




Board Composition

- Average number of directors
- Average number of independent directors



Separation of Chair and CEO Roles**





Multiple Classes of Common Stock

Excludes FPIs (subject to home jurisdiction governance rules).



*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

**Excludes three issuers that did not have a Chair at the time of IPO.

Secondary Component and Directed Share Programs (DSPs)




Deal Structure: Insiders Purchasing in IPO




Excludes purchases through a DSP.

Lock-ups and Carve-outs




Lock-up Release

- Lead left bookrunner only - 0%
- Multiple bookrunners - 100%




Carve-out for Acquisitions/ Joint Ventures




Company Lock-up/ Carve-out by Cap

- 5% carve-out - 100%

Fees and Expenses





*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.





Appendix A - Sponsor-Backed IPOs

Sponsor-Backed Overview: Sector Analysis






Sponsor-Backed Overview: Deal Size & Market Capitalization




*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Deal Execution





Secondary Sales



Sponsor-Backed IPOs with a Secondary Component



- Sponsor-Backed IPOs without a secondary component - 27%
- Sponsor-Backed IPOs with a secondary component without management selling - 73%



Sponsor-Backed IPOs with a Secondary Component and Management Selling


- Sponsor-Backed IPOs without a secondary component - 43%
- Sponsor-Backed IPOs with a secondary component without management selling - 57%

Time to IPO and SEC Comments




*Excludes prior SEC-reviewed issuers.

Non-GAAP Financial Measures




**EBITDA and/or
Adjusted EBITDA
Disclosure**




**SEC Comments:
Non-GAAP
Financial Measures
Comments**

Excludes prior SEC-reviewed issuers.

Corporate Governance




IPOs with Multiple Classes of Common Stock




Issuers Eligible to Elect Controlled Company Exemption

Excludes FPIs (subject to home jurisdiction governance rules).

Board Structure




IPOs with Classified Boards



Average Number of Directors

- Sponsor-Backed - 8
- Non-Sponsor-Backed - 7






Average Number of Independent Directors

- Sponsor-Backed - 5
- Non-Sponsor-Backed - 6



Excludes FPIs (subject to home jurisdiction governance rules).

Anti-Takeover



Excludes FPIs (subject to home jurisdiction governance rules).


Fees and Expenses




*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriter in the form of a discount or commission.

Appendix B - Foreign Private Issuers

Market Overview: Foreign Private Issuers



FPI Headquarters





FPI Headquarters

- 2018
- 2014-2017

Sector Analysis

There was a greater percentage of TMT and Consumer/Retail IPOs among FPIs as compared to the overall market.



There was a lower percentage of Health Care IPOs among FPIs as compared to the overall market.



Five-Year FPI Sector Trend Analysis



- 2014-2017
- 2018

Deal Size




Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

Market Capitalization at Pricing





Deal Execution

The over-allotment option was exercised in a lower percentage of FPI IPOs than in the overall market.




**Exercise of
Over-Allotment
Option**

Pricing and Aftermarket Performance




Time to IPO




*Excludes prior SEC-reviewed issuers and an additional two issuers in 2014, one in 2015, two in 2016, and nine in 2017 with time from first submission/filing to pricing of greater than 18 months.

Financial Information: Financial Statements




*FPIs are not required to include quarterly financial statements.



Accounting Method Used

- IFRS - 9%
- U.S. GAAP - 91%




Disclosure of EBITDA and/or Adjusted EBITDA

- Disclosed - 41%
- Not disclosed - 59%


FPIs are permitted to include financial statements prepared in accordance with IFRS.

SEC Comments

FPIs received, on average, more comments from the SEC than non-FPIs.



Average Number of First Round SEC Comments





SEC Comment Subject Matter

● FPI IPO
● Non-FPI IPO



Excludes three prior SEC-reviewed issuers.

Secondary Component and Insiders Purchasing



*Does not include purchases through a DSP.

Fees and Expenses



*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.

